Laurion Capital Management LP acquired a new stake in shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 117,700 shares of the company’s stock, valued at approximately $3,372,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. American International Group Inc. acquired a new position in Crinetics Pharmaceuticals during the 3rd quarter worth about $132,000. Bank of New York Mellon Corp acquired a new position in Crinetics Pharmaceuticals during the 3rd quarter worth about $453,000. Dean Capital Investments Management LLC acquired a new position in Crinetics Pharmaceuticals during the 3rd quarter worth about $701,000. Foresite Capital Management IV LLC acquired a new position in Crinetics Pharmaceuticals during the 3rd quarter worth about $1,421,000. Finally, Victory Capital Management Inc. acquired a new position in Crinetics Pharmaceuticals during the 3rd quarter worth about $2,716,000. 67.26% of the stock is currently owned by institutional investors.
Several research analysts have commented on CRNX shares. Zacks Investment Research raised Crinetics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 6th. JPMorgan Chase & Co. cut their target price on Crinetics Pharmaceuticals from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, November 14th. Leerink Swann started coverage on Crinetics Pharmaceuticals in a report on Monday, August 13th. They set an “outperform” rating and a $43.00 target price on the stock. Finally, Piper Jaffray Companies started coverage on Crinetics Pharmaceuticals in a report on Monday, August 13th. They set an “overweight” rating and a $40.00 target price on the stock.
Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.04). The business had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.28 million. Crinetics Pharmaceuticals had a negative net margin of 972.23% and a negative return on equity of 78.81%. As a group, analysts predict that Crinetics Pharmaceuticals Inc will post -2.2 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2018/12/08/laurion-capital-management-lp-invests-3-37-million-in-crinetics-pharmaceuticals-inc-crnx.html.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.
Further Reading: Compound Interest and Why It Matters When Investing
Want to see what other hedge funds are holding CRNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals Inc (NASDAQ:CRNX).
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.